Search Icon
Search Icon
close-panel

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Get Notifications

Sign up to receive email updates from Charlotte Lozier Institute.

This field is for validation purposes and should be left unchanged.

Become A Defender of Life

Your donation helps us continue to provide world-class research in defense of life.

DONATE

Charlotte Lozier Institute

Phone: 202-223-8073
Fax: 571-312-0544

2776 S. Arlington Mill Dr.
#803
Arlington, VA 22206

Life & the Law

SCOTUS Confirms First Amendment Protects Pregnancy Center Donors From Nosey Abortion States

A New Jersey-based pro-life pregnancy center may proceed with its federal challenge to lawfare waged against it by the state’s Democrat attorney general, the Supreme Court unanimously ruled in a 25-page decision on Wednesday.

As The Federalist previously reported, First Choice Women’s Resource Centers, Inc. v. Platkin came about when New Jersey’s Democrat-run government began investigating First Choice Women’s Resource Centers over seemingly baseless concerns that it was misleading its donors and misrepresenting its services. This investigation culminated in then-Attorney General Matthew Platkin’s office issuing First Choice a subpoena in an attempt to strong-arm the nonprofit into doxxing its donors and forfeiting information to a state with a strong abortion activism agenda.

Continue Reading at The Federalist >>

Latest Posts

October 6, 2026 A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification. A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review October 6, 2026 Ultrasound image showing the side profile of a human baby Inside The Government Decision That Opened Up Abortion Pill Floodgates October 6, 2026 A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined. Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

You Might Also Be Interested In

A magnifying glass rests on three wooden blocks that spell out FDA, symbolizing a review of the REMS modification.

A Critical Analysis of the FDA’s 2021 Mifepristone REMS Modification Rationale Review

A sign for the FDA featuring the agency’s logo and circular seals in front of a brick government building, where clinical guidance for mifepristone REMS is often determined.

Unintended Consequences of the FDA’s 2021-2023 Risk Evaluation and Mitigation Strategy (REMS) Changes to Mifepristone

A person in a white shirt dropping an abortion ballot into a white box against a yellow background.

Abortion on the Ballot in November

October 2, 2026

Become A Defender of Life

Your donation helps us continue to provide
world-class research in defense of life.

BECOME A PARTNER
cta-image